Your browser doesn't support javascript.
loading
Correction to: A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
Nakayama, Hideki; Ogawa, Chitose; Sekimizu, Masahiro; Fujisaki, Hiroyuki; Kosaka, Yoshiyuki; Hashimoto, Hiroya; Saito, Akiko M; Horibe, Keizo.
Affiliation
  • Nakayama H; Department of Pediatrics, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan. hnkym415@gmail.com.
  • Ogawa C; Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Sekimizu M; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Fujisaki H; Department of Pediatrics, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Kosaka Y; Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan.
  • Hashimoto H; Department of Hematology and Oncology, Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan.
  • Saito AM; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
  • Horibe K; Core Laboratory, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan.
Int J Hematol ; 117(5): 786, 2023 May.
Article in En | MEDLINE | ID: mdl-36943610
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int J Hematol Journal subject: HEMATOLOGIA Year: 2023 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int J Hematol Journal subject: HEMATOLOGIA Year: 2023 Document type: Article Affiliation country: Country of publication: